{
    "clinical_study": {
        "@rank": "147999", 
        "acronym": "BRAVO", 
        "arm_group": [
            {
                "arm_group_label": "Study Juice", 
                "arm_group_type": "Experimental", 
                "description": "3,300 mg of Omega-3 HUFAs per day for 6 months\nOther names: none"
            }, 
            {
                "arm_group_label": "Placebo Juice", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3,300 mg of macadamia nut oil per day for 6 months\nOther names: none"
            }
        ], 
        "brief_summary": {
            "textblock": "The BRAVO study seeks to determine if dietary supplementation with omega-3 highly\n      unsaturated fatty acids (omega-3 HUFAs) reduces the risk for serious suicidal behaviors,\n      suicidal thinking, negative emotions, and symptoms associated with suicide risk, in a\n      Veteran population that is at risk for suicidal behaviors.  This study seeks to evaluate the\n      efficacy of omega-3 HUFAs among a representative population of US Veterans already receiving\n      appropriate medical care so that if successful, these results can be readily applied to\n      broader populations."
        }, 
        "brief_title": "The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Suicide", 
        "condition_browse": {
            "mesh_term": "Suicide"
        }, 
        "detailed_description": {
            "textblock": "The BRAVO study seeks to determine if dietary supplementation with omega-3 highly\n      unsaturated fatty acids (omega-3 HUFAs) reduces the risk for serious suicidal behaviors,\n      suicidal thinking, negative emotions, and symptoms associated with suicide risk, in a\n      Veteran population that is at risk for suicidal behaviors.  Changes in cognitive processes\n      specific to suicide risk will be evaluated, including implicit associations, response\n      inhibition and sustained attention. Sub-analyses will evaluate efficacy in reducing\n      depressive symptoms, alcohol and nicotine use among Veterans with concomitant significant\n      depressive symptoms, and alcohol and nicotine use disorders. In addition, a sub-study will\n      utilize functional magnetic resonance imaging (fMRI) to evaluate the neuropsychological and\n      neurophysiological effects of the omega-3 HUFAs.  This study seeks to evaluate the efficacy\n      of omega-3 HUFAs among a representative population of US Veterans already receiving\n      appropriate medical care so that if successful, these results can be readily applied to\n      broader populations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria- Primary study\n\n          1. a US Military Services Veteran identified as part of either of the following groups:\n\n               1. VA Veterans that have been identified as being at risk of suicide and have a\n                  current, active treatment plan at the VA\n\n               2. If enrolling subjects from outside the VA or the subject is a non-VA veteran,\n                  the subject must presently be under the care of a mental health professional\n\n          2. age 18 - 90\n\n          3. within the last 3 months, either\n\n               1. a suicide attempt, or\n\n               2. an inpatient admission with suicide risk, or\n\n               3. a clinical diagnosis based on the BRAVO psychiatrist-administered\n                  Columbia-Suicide Severity Rating Scale (C-SSRS) and psychiatrist review of\n                  participant medical history and physical, or\n\n               4. a score of 0 or greater on the Implicit Associations Test-Suicide (IAT-S)\n\n          4. participant can safely eat walnuts, pecans, almonds, peanuts and all other nuts\n\n          5. participant can safely eat apples, pears, pomegranates, aronia, jackfruit, and\n             passion fruit\n\n          6. participant can safely eat the herb rosemary, and the fish salmon, trout and cod\n\n          7. participant can safely drink and eat food that contain whey and/or milk protein\n\n          8. willingness to drink the juice boxes 3 times each day for 6 months\n\n          9. have  a stable residence with adequate space to store the juice\n\n         10. capacity to provide written informed consent\n\n        Additional inclusion criteria for Depressive Symptoms sub-analysis\n\n          1. enrollment in the primary study of suicide risk reduction\n\n          2. a Beck Depression Inventory \u226530\n\n          3. a diagnosis of a depressive disorder\n\n        Additional inclusion criteria for Alcohol and Nicotine use sub-analysis\n\n          1. enrollment in the primary study of suicide risk reduction\n\n          2. diagnosis of an alcohol use disorder or \"at risk drinking patterns\"\n\n          3. self-report of smoking >10 cigarettes/d.\n\n        Exclusion criteria-\n\n          1. unstable medical conditions requiring immediate attention or medical conditions that\n             preclude potential study participation for the duration of the study\n\n          2. history of seizures, except for febrile seizures during childhood\n\n          3. persons who are diagnosed with diabetes\n\n          4. those taking Isotretinoin (Accutane )\n\n          5. allergy, hypersensitivity, or intolerance to fish oils or omega-3 fats\n\n          6. allergy, hypersensitivity, or intolerance to Macadamia nuts or any nuts such as\n             almonds, walnuts, pecans, peanuts, etc.\n\n          7. allergy, hypersensitivity, or intolerance to eat apples, pears, pomegranates, aronia,\n             jackfruit, and passion fruit\n\n          8. allergy, hypersensitivity, or intolerance to the herb rosemary, and the fish: salmon,\n             trout and cod\n\n          9. allergy, hypersensitivity, or intolerance to whey and/or milk protein\n\n         10. life threatening medical conditions or life expectancy of less than 6 months.\n\n         11. pregnancy or lactation or intention to become pregnant within the next 12 months\n\n         12. acute intoxication or withdrawal from alcohol or other substances (to be determined\n             by a clinical team member)\n\n         13. a cognitive impairment severe enough to preclude informed consent or valid responses\n             on self-report questionnaires\n\n         14. Body Mass Index (BMI) <18.5\n\n         15. evidence of disordered eating or risk of malnutrition based on the Eating Attitudes\n             Test (EAT-26)\n\n         16. relapsing of remitting Multiple Sclerosis\n\n         17. unstable or rapidly progressive neurological disease\n\n         18. history of significant behavioral instability\n\n         19. participating in another research study\n\n         20. individuals that take anticoagulants regularly including; high dose aspirin; warfarin\n             or Coumadin\n\n        Additional exclusion criteria for fMRI Study Only (40 individuals):\n\n          -  inability or unwillingness to participate in an fMRI scan,\n\n          -  presence of metallic objects in the body that would interfere with the scan\n\n          -  pronounced claustrophobia\n\n          -  body weight >300 pounds"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901887", 
            "org_study_id": "BRAVO2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study Juice", 
                "description": "The intervention will be 3 boxes/day for 6 months of SMARTFISH\u00ae Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).", 
                "intervention_name": "Study Juice", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SMARTFISH\u00ae Nutrifriend 1100", 
                    "Omega-3 formulated juice"
                ]
            }, 
            {
                "arm_group_label": "Placebo Juice", 
                "description": "The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.", 
                "intervention_name": "Placebo Juice", 
                "intervention_type": "Drug", 
                "other_name": "Other names: Smartfish (placebo juice)"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Veterans", 
            "Suicidality"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "email": "BRAVO@musc.edu", 
                "last_name": "Bravo Study Line", 
                "phone": "888-322-6884"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": {
                "last_name": "Bernadette Marriott, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans", 
        "other_outcome": [
            {
                "description": "Examine to see if higher blood levels of omega-3 HUFAs correlate with scores on the Beck Depression Inventory, and increase likelihood of a 50% reduction in depressive symptoms.", 
                "measure": "Impact of omega-3 HUFA supplementation among subjects with moderate to severe depressive symptoms to evaluate efficacy for clinically significant depressive symptoms.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Examine to see if dietary supplementation with omega-3 HUFAs decreases alcohol use in alcohol-dependent individuals; decreases alcohol consumption in non-alcohol-dependent individuals who endorse risky alcohol use in the past 12 months; decreases obsessive and compulsive thoughts about alcohol; and, decreases use of cigarettes among persons who smoke >10 cigarettes/day.  Examine to see if decreases in alcohol consumption are associated with decreases in negative affect and impulsivity; and, if they are associated with decreased suicidal ideation/behaviors.", 
                "measure": "Impact of dietary supplementation with omega-3 fatty acids on alcohol consumption in suicidal Veterans with alcohol use disorders.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Determine if dietary supplementation with omega-3 fatty acids increases activation of frontal brain regions associated with risky decision-making (e.g., orbitofrontal cortex); and those associated with suicide attempt recall (e.g., medial prefrontal cortex.)", 
                "measure": "Impact of an omega-3 HUFA intervention on prefrontal hypo activation to risky decision-making and recall of past suicidal events in suicide attempters, using functional Magnetic Resonance Imaging (fMRI).", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Determine if increases in frontal activation to risky decision-making and recall of past suicidal events from baseline to 5-months post treatment-initiation are associated with less suicidal ideation and behavior at > 5-months post treatment-initiation.", 
                "measure": "Suicidal ideation and behavior at 5-months post treatment-initiation by fMRI.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Bernadette Marriott, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Examine to see if dietary supplementation with omega-3 HUFAs results in fewer episodes of a New Episode of Significant Suicide Risk (NESSR)*, reduces symptom assessment scores for suicidality, reduces implicit associations with suicide and death, and improves performance scores on suicide related cognition tests.\n* A NESSR is defined as the occurrence of any of the following: a) a suicide death, or b) a suicide attempt, or c) an inpatient admission with suicide risk, or d) a clinical diagnosis based on the BRAVO psychiatrist-administered Columbia-Suicide Severity Rating Scale and psychiatrist review of participant medical history and physical.", 
            "measure": "Impact of omega-3 HUFA supplementation on suicidal behaviors and thinking among Veterans.", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "9643729", 
                "citation": "Hibbeln JR. Fish consumption and major depression. Lancet. 1998 Apr 18;351(9110):1213. No abstract available."
            }, 
            {
                "PMID": "9715354", 
                "citation": "Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry. 1998 Aug 15;44(4):235-42."
            }, 
            {
                "PMID": "16949263", 
                "citation": "McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids. 2006 Oct-Nov;75(4-5):329-49. Epub 2006 Sep 1. Review."
            }, 
            {
                "PMID": "21367944", 
                "citation": "Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011 May;93(5):950-62. doi: 10.3945/ajcn.110.006643. Epub 2011 Mar 2."
            }, 
            {
                "PMID": "19136836", 
                "citation": "Hibbeln JR. Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev Nutr Diet. 2009;99:17-30. doi: 10.1159/000192992. Epub 2009 Jan 9. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901887"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Bernadette Marriott", 
            "investigator_title": "Professor Department of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Examine to see if dietary supplementation with omega-3 HUFAs reduces symptoms of perceptions of daily stress, anxiety, depression, and  hopelessness.", 
                "measure": "Impact of omega-3 HUFA supplementation on symptoms of negative affect associated with suicide risk among Veterans.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Examine to see if dietary supplementation with omega-3 HUFAs lowers the number of moderate to severe symptoms of PTSD, and decreases the severity of symptoms of PTSD among subjects with moderate to severe symptoms.", 
                "measure": "Impact of omega-3 HUFA supplementation on symptoms of post-traumatic stress disorder (PTSD) associated with suicide risk among Veterans.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Examine to see if dietary supplementation with omega-3 HUFAs improves sustained attention, response inhibition, and cognitive control;  determine if changes in cognitive parameters are associated with changes in negative affect; and, determine if cognitive changes are associated with changes in suicide parameters.", 
                "measure": "Impact of omega-3 HUFA supplementation on symptoms of cognitive functioning associated with suicide risk among Veterans.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}